The effect of sickle cell genotype on the pharmacokinetic properties of artemether-lumefantrine in Tanzanian children

Abdulla, 2008, Efficacy and safety of artemether-lumefantrine dispersible tablets compared with crushed commercial tablets in African infants and children with uncomplicated malaria: a randomised, single-blind, multicentre trial, Lancet, 372, 1819, 10.1016/S0140-6736(08)61492-0 Adjei, 2014, A randomized trial of artesunate-amodiaquine versus artemether-lumefantrine in Ghanaian paediatric sickle cell and non-sickle cell disease patients with acute uncomplicated malaria, Malar. J., 13, 369, 10.1186/1475-2875-13-369 Adjei, 2019, Population pharmacokinetic estimates suggest elevated clearance and distribution volume of desethylamodiaquine in pediatric patients with sickle cell disease treated with artesunate-amodiaquine, Curr. Ther. Res. Clin. Exp., 90, 9, 10.1016/j.curtheres.2019.01.005 Ambe, 2001, Associated morbidities in children with sickle-cell anaemia presenting with severe anaemia in a malarious area, Trop. Doct., 31, 26, 10.1177/004947550103100109 Ambrose, 2018, High birth prevalence of sickle cell disease in Northwestern Tanzania, Pediatr. Blood Cancer, 65, 10.1002/pbc.26735 Ambrose, 2020, Surveillance for sickle cell disease, United Republic of Tanzania, Bull. World Health Organ., 98, 859, 10.2471/BLT.20.253583 Anderson, 2009, Mechanistic basis of using body size and maturation to predict clearance in humans, Drug Metabol. Pharmacokinet., 24, 25, 10.2133/dmpk.24.25 Ashley, 2007, Pharmacokinetic study of artemether-lumefantrine given once daily for the treatment of uncomplicated multidrug-resistant falciparum malaria, Trop. Med. Int. Health, 12, 201, 10.1111/j.1365-3156.2006.01785.x Bindschedler, 2000, Cardiac effects of co-artemether (artemether/lumefantrine) and mefloquine given alone or in combination to healthy volunteers, Eur. J. Clin. Pharmacol., 56, 375, 10.1007/s002280000155 Blessborn, 2013, Heat stabilization of blood spot samples for determination of metabolically unstable drug compounds, Bioanalysis, 5, 31, 10.4155/bio.12.294 Byakika-Kibwika, 2012, Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adults, J. Antimicrob. Chemother., 67, 1217, 10.1093/jac/dkr596 Darbari, 2011, Increased clearance of morphine in sickle cell disease: implications for pain management, J. Pain, 12, 531, 10.1016/j.jpain.2010.10.012 Djimde, 2009, Understanding the pharmacokinetics of coartem, Malar. J., 8, S4, 10.1186/1475-2875-8-S1-S4 Eridani, 2011, Sickle cell protection from malaria, Hematol. Rep., 3, e24, 10.4081/hr.2011.e24 Ezzet, 2000, Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria, Antimicrob. Agents Chemother., 44, 697, 10.1128/AAC.44.3.697-704.2000 German, 2009, Lopinavir/Ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers, J. Acquir. Immune Defic. Syndr., 51, 424, 10.1097/QAI.0b013e3181acb4ff Gremse, 1998, Hepatic function as assessed by lidocaine metabolism in sickle cell disease, J. Pediatr., 132, 989, 10.1016/S0022-3476(98)70396-8 Hatz, 2008, Treatment of acute uncomplicated falciparum malaria with artemether-lumefantrine in nonimmune populations: a safety, efficacy, and pharmacokinetic study, Am. J. Trop. Med. Hyg., 78, 241, 10.4269/ajtmh.2008.78.241 Hietala, 2010, Population pharmacokinetics and pharmacodynamics of artemether and lumefantrine during combination treatment in children with uncomplicated falciparum malaria in Tanzania, Antimicrob. Agents Chemother., 54, 4780, 10.1128/AAC.00252-10 Horst, 2016, Pharmacokinetics and analgesic effects of methadone in children and adults with sickle cell disease, Pediatr. Blood Cancer, 63, 2123, 10.1002/pbc.26207 Howie, 2011, Blood sample volumes in child health research: review of safe limits, Bull. World Health Organ., 89, 46, 10.2471/BLT.10.080010 Huang, 2013, Determination of artemether and dihydroartemisinin in human plasma with a new hydrogen peroxide stabilization method, Bioanalysis, 5, 1501, 10.4155/bio.13.91 Huang, 2018, Strong correlation of lumefantrine concentrations in capillary and venous plasma from malaria patients, PLoS One, 13 Hughes, 2020, Efavirenz-based antiretroviral therapy reduces artemether-lumefantrine exposure for malaria treatment in HIV-infected pregnant women, J. Acquir. Immune Defic. Syndr., 83, 140, 10.1097/QAI.0000000000002237 Ittarat, 1998, Effects of alpha-thalassemia on pharmacokinetics of the antimalarial agent artesunate, Antimicrob. Agents Chemother., 42, 2332, 10.1128/AAC.42.9.2332 Kamchonwongpaisan, 1994, Resistance to artemisinin of malaria parasites (Plasmodium falciparum) infecting alpha-thalassemic erythrocytes in vitro. Competition in drug accumulation with uninfected erythrocytes, J. Clin. Invest., 93, 467, 10.1172/JCI116994 Kane, 2022 Karunajeewa, 2004, Disposition of artesunate and dihydroartemisinin after administration of artesunate suppositories in children from Papua New Guinea with uncomplicated malaria, Antimicrob. Agents Chemother., 48, 2966, 10.1128/AAC.48.8.2966-2972.2004 Kloprogge, 2013, Population pharmacokinetics of lumefantrine in pregnant and nonpregnant women with uncomplicated Plasmodium falciparum malaria in Uganda, CPT Pharmacometrics Syst. Pharmacol., 2, e83, 10.1038/psp.2013.59 Kloprogge, 2015, Lumefantrine and desbutyl-lumefantrine population pharmacokinetic-pharmacodynamic relationships in pregnant women with uncomplicated Plasmodium falciparum malaria on the Thailand-Myanmar border, Antimicrob. Agents Chemother., 59, 6375, 10.1128/AAC.00267-15 Kloprogge, 2018, Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: a pharmacokinetic-pharmacodynamic meta-analysis, PLoS Med., 15, 10.1371/journal.pmed.1002579 Komba, 2009, Malaria as a cause of morbidity and mortality in children with homozygous sickle cell disease on the coast of Kenya, Clin. Infect. Dis., 49, 216, 10.1086/599834 Kredo, 2016, The interaction between artemether-lumefantrine and lopinavir/ritonavir-based antiretroviral therapy in HIV-1 infected patients, BMC Infect. Dis., 16, 30, 10.1186/s12879-016-1345-1 Lefevre, 1999, Clinical pharmacokinetics of artemether and lumefantrine (Riamet (R)), Clin. Drug Invest., 18, 467, 10.2165/00044011-199918060-00006 Lefevre, 2002, Interaction trial between artemether-lumefantrine (Riamet) and quinine in healthy subjects, J. Clin. Pharmacol., 42, 1147, 10.1177/009127002401382632 Lohy Das, 2018, Population pharmacokinetics of artemether, dihydroartemisinin, and lumefantrine in Rwandese pregnant women treated for uncomplicated Plasmodium falciparum malaria, Antimicrob. Agents Chemother., 62, 10.1128/AAC.00518-18 Maganda, 2015, The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment, Malar. J., 14, 179, 10.1186/s12936-015-0695-2 Makani, 2010, Malaria in patients with sickle cell anemia: burden, risk factors, and outcome at the outpatient clinic and during hospitalization, Blood, 115, 215, 10.1182/blood-2009-07-233528 Maksoud, 2018, Population pharmacokinetics of cefotaxime and dosage recommendations in children with sickle cell disease, Antimicrob. Agents Chemother., 62, 10.1128/AAC.00637-17 McAuley, 2010, High mortality from Plasmodium falciparum malaria in children living with sickle cell anemia on the coast of Kenya, Blood, 116, 1663, 10.1182/blood-2010-01-265249 McGready, 2006, The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malaria, Eur. J. Clin. Pharmacol., 62, 1021, 10.1007/s00228-006-0199-7 Michael, 2017, The malaria testing and treatment landscape in mainland Tanzania, Malar. J., 16, 202, 10.1186/s12936-017-1819-7 Mwesigwa, 2010, Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda, Antimicrob. Agents Chemother., 54, 52, 10.1128/AAC.00679-09 Ndeffo Mbah, 2015, Comparing the impact of artemisinin-based combination therapies on malaria transmission in sub-Saharan Africa, Am. J. Trop. Med. Hyg., 92, 555, 10.4269/ajtmh.14-0490 Ndounga, 2015, Artesunate-amodiaquine versus artemether-lumefantrine for the treatment of acute uncomplicated malaria in Congolese children under 10 years old living in a suburban area: a randomized study, Malar. J., 14, 423, 10.1186/s12936-015-0918-6 Olafuyi, 2017, Development of a paediatric physiologically based pharmacokinetic model to assess the impact of drug-drug interactions in tuberculosis co-infected malaria subjects: a case study with artemether-lumefantrine and the CYP3A4-inducer rifampicin, Eur. J. Pharmaceut. Sci., 106, 20, 10.1016/j.ejps.2017.05.043 Pearson, 1979, Developmental aspects of splenic function in sickle cell diseases, Blood, 53, 358, 10.1182/blood.V53.3.358.358 Salman, 2011, Population pharmacokinetics of artemether, lumefantrine, and their respective metabolites in Papua New Guinean children with uncomplicated malaria, Antimicrob. Agents Chemother., 55, 5306, 10.1128/AAC.05136-11 Sugiarto, 2017, Pharmacokinetic considerations for use of artemisinin-based combination therapies against falciparum malaria in different ethnic populations, Expet Opin. Drug Metabol. Toxicol., 13, 1115, 10.1080/17425255.2017.1391212 Sugiarto, 2018, Artemisinin therapy for malaria in hemoglobinopathies: a systematic review, Clin. Infect. Dis., 66, 799, 10.1093/cid/cix785 Sugiarto, 2022, The pharmacokinetic properties of artemether and lumefantrine in Malaysian patients with Plasmodium knowlesi malaria, Br. J. Clin. Pharmacol., 88, 691, 10.1111/bcp.15001 Taneja, 2013, Dried blood spots in bioanalysis of antimalarials: relevance and challenges in quantitative assessment of antimalarial drugs, Bioanalysis, 5, 2171, 10.4155/bio.13.180 Tarning, 2009, Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria, Antimicrob. Agents Chemother., 53, 3837, 10.1128/AAC.00195-09 Taylor, 2012, Haemoglobinopathies and the clinical epidemiology of malaria: a systematic review and meta-analysis, Lancet Infect. Dis., 12, 457, 10.1016/S1473-3099(12)70055-5 Tchaparian, 2016, Population pharmacokinetics and pharmacodynamics of lumefantrine in young Ugandan children treated with artemether-lumefantrine for uncomplicated malaria, J. Infect. Dis., 214, 1243, 10.1093/infdis/jiw338 Wong, 2011, Desbutyl-lumefantrine is a metabolite of lumefantrine with potent in vitro antimalarial activity that may influence artemether-lumefantrine treatment outcome, Antimicrob. Agents Chemother., 55, 1194, 10.1128/AAC.01312-10 2021 Zimmerman, 2019, Duration of pediatric clinical trials submitted to the US Food and Drug Administration, JAMA Pediatr., 173, 60, 10.1001/jamapediatrics.2018.3227